Pyrimidine Triones as Potential Activators of p53 Mutants
2024
Maryam M. Jebril Fallatah | Özlem Demir | Fiona Law | Linda Lauinger | Roberta Baronio | Linda Hall | Elodie Bournique | Ambuj Srivastava | Landon Tyler Metzen | Zane Norman | Rémi Buisson | Rommie E. Amaro | Peter Kaiser
p53 is a crucial tumor suppressor in vertebrates that is frequently mutated in human cancers. Most mutations are missense mutations that render p53 inactive in suppressing tumor initiation and progression. Developing small-molecule drugs to convert mutant p53 into an active, wild-type-like conformation is a significant focus for personalized cancer therapy. Prior research indicates that reactivating p53 suppresses cancer cell proliferation and tumor growth in animal models. Early clinical evidence with a compound selectively targeting p53 mutants with substitutions of tyrosine 220 suggests potential therapeutic benefits of reactivating p53 in patients. This study identifies and examines the UCI-1001 compound series as a potential corrector for several p53 mutations. The findings indicate that UCI-1001 treatment in p53 mutant cancer cell lines inhibits growth and reinstates wild-type p53 activities, including DNA binding, target gene activation, and induction of cell death. Cellular thermal shift assays, conformation-specific immunofluorescence staining, and differential scanning fluorometry suggest that UCI-1001 interacts with and alters the conformation of mutant p53 in cancer cells. These initial results identify pyrimidine trione derivatives of the UCI-1001 series as candidates for p53 corrector drug development.
Show more [+] Less [-]Bibliographic information
This bibliographic record has been provided by Directory of Open Access Journals